Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a product name.
BioCentury | Sep 9, 2024
Management Tracks
Doug Williams takes on CAR T cell access as TriArm CEO
Veteran of Biogen, Sana to head cross-border company TriArm Therapeutics
BioCentury | Aug 30, 2024
Market Access
BioCentury snap survey shows lack of concern about IRA prices, anxiety about future
Biopharma industry reacts calmly to first IRA prices
BioCentury | Aug 15, 2024
Market Access
No surprises: CMS unveils prices for first set of IRA-negotiated drugs
Discounts range from 38% for Imbruvica to 79% for diabetes drug Januvia
BioCentury | Apr 16, 2024
Politics, Policy & Law
How CMS’s IRA methodology will steer medicine
Choice of comparator will determine if the agency prioritizes innovation or price
BioCentury | Feb 2, 2024
Market Access
Manufacturers should think twice before developing a self-administered biosimilar
Samsung Bioepis report says Humira has 97% of the adalimumab market almost a year after it lost exclusivity
BioCentury | May 16, 2023
Politics, Policy & Law
FTC fires first shot in pharma war
Antitrust agency making good on promise to use untested theories to block pharma M&A
BioCentury | Dec 12, 2022
Deals
Returning to its roots, Amgen adding growth with $28.7B deal for Horizon
Acquisition bolsters inflammation, autoimmune portfolio after oncology franchise comes under pressure
BioCentury | Nov 11, 2022
Discovery & Translation
S&K’s small molecule TNF inhibitor; plus Actym’s engineered bacteria platform and more
BioCentury’s roundup of translational news
BioCentury | Aug 4, 2022
Deals
Amgen sees Tavneos as growth opportunity with $4B ChemoCentryx buyout
With patent expirations ahead, deal gives Amgen immunology asset approved for vasculitis indication, with potential for label expansions
BioCentury | Jun 1, 2021
Deals
For $400M up front, Amgen gains Dupixent rival in Kyowa Kirin’s OX40 antibody
OX40 program to enter Phase III testing for atopic dermatitis in 1H22
Items per page:
1 - 10 of 979